<DOC>
	<DOCNO>NCT00507052</DOCNO>
	<brief_summary>In opinion , worth check ability antioxidant therapy produce favorable effect Residual Renal Function . The aim study investigate effect N-acetylsysteine RRF prevalent HD patient .</brief_summary>
	<brief_title>Effect N-Acetylcysteine Residual Renal Function Chronic Hemodialysis Patients</brief_title>
	<detailed_description>Background Preserving residual renal function ( RRF ) always primary clinical goal every nephrologists manage patient chronic kidney disease yet dialysis . RRF patient dialysis proven consistent powerful predictor mortality . This particularly evident patient treat peritoneal dialysis ( PD ) : CANUSA study show RRF dialysis dose significant predictive power mortality [ 1 ] . Interestingly , study examine contribution RRF outcome hemodialysis ( HD ) patient . This particularly unfortunate HD patient count 90 % dialysis population Israel USA . A single study show persistence RRF significantly improve patient ' outcome [ 2 ] . Moreover , well know RRF deteriorate rapidly HD patient PD patient [ 3 ] . Preservation RRF remain unresolved problem dialysis patient . The exact mechanism rapid loss RRF HD fully understood . Several experimental clinical study show variety vascular event increase oxidative stress dialysis patient may due inhibition nitric oxide ( NO ) synthesis ADMA ( Asymmetric Dimethylarginine ) , know endogenous inhibitor NO synthetase [ 4 ] . ADMA may significantly reduce dialysis [ 5 ] . Metabolism ADMA primarily enzyme DDAH , activity decrease inflammation , oxidative stress , diabetes mellitus hypercholesterolemia [ 6 ] . Based current knowledge , treatment aim reduce oxidative stress decrease ADMA level [ 6 ] , logical suggest therapy might help preserve RRF HD patient . In opinion , worth check ability antioxidant therapy produce favorable effect RRF . One preliminary study effect antioxidant Vitamin E show small beneficial effect ADMA chronic kidney disease [ 7 ] . N-Acetylcysteine ( NAC ) active antioxidant prove safe beneficial hemodialysis patent [ 8 ] . In recent study , NAC effectively reduce ototoxic effect gentamicin chronic hemodialysis patient [ 9 ] . The aim study investigate effect N-acetylsysteine RRF prevalent HD patient . Methods . Study population . The study include 20 patient ESRD , treat chronic hemo- dialysis Assaf Harofeh Medical Center . Patients exclude study : 1 . Patients acute renal failure 2 . Currently treat antioxidant ( NAC , vitamin E ets . ) Study protocol . We plan study prospective cross-sectional study every patient serve his/her control . Al patient continue previous dialysis drug regimen . After performance baseline clinical laboratory examination patient receive orally NAC 1200 mg x 2/day 2 week . At end therapy , follow PET Kt/V examination perform . These baseline follow clinical laboratory examination perform outpatient basis dialysis unit . The clinical monitoring patient include : 1 . Blood Pressure Heart Rate - two visit . 2. Review current medication dos . 3 . Body weight - two visit . 4 . Dialysis adequacy : Kt/V 6 . Residual renal function examination : 24 hour urinary collection urea creatinine calculation CCT residual Kt/V baseline follow visit . 7 . Biochemical study : ADMA , DDAH , NO - baseline follow visit . Statistical analysis The statistical analysis perform use statistical software SPSS-version 10 . Parametric data express mean Â± standard deviation compare standard t-test . Non-parametric data compare use chi square test . p value 0.05 less consider significant . References 1 . Bargman J , Thorpe K , Churchill D. Relative contribution residual renal function peritoneal clearance adequacy dialysis : reanalysis CANUSA study . J Am Soc Nephrol 2001 ; 12 : 2158-62 2 . Shemin D , Bostom A , Laliberty P , Dworkin L. Residual renal function mortality risk hemodialysis patient . Am J Kidney Dis . 2001 ; 38 : 85-90 3 . Moist L , Port F , Orzol S et al . Predictors loss residual renal function among new dialysis patient . J Am Soc Nephrol 2000 ; 11 : 556-564 . 4 . Vallance P , Leone A , Calver A , Collier J , Moncada S. Accumulation endogenous inhibitor nitric oxide synthesis chronic renal failure . Lancet . 1992 Mar 7 ; 339 ( 8793 ) :572-5 . 5 . Kielstein J , Boger R , Bode-Boger S et al . Asymmetric Dimethylarginine Plasma Concentrations Differ Patients End-Stage Renal Disease . J Am Soc Nephrol 1999 ; 10:594-600 6 . Kielstein J , Zoccali C. Asymmetric dimethylarginine : cardiovascular risk factor uremic toxin come age ? Am J Kidney Dis . 2005 ; 46 ( 2 ) :186-202 . 7 . Saran R , Novak J , Desai A et al . Impact vitamin E plasma asymmetric dimethylarginine ( ADMA ) chronic kidney disease ( CKD ) : pilot study . Nephrol Dial Transplant . 2003 Nov ; 18 ( 11 ) :2415-20 . 8 . Tepel M , van der Giet M , Statz M et al . The antioxidant acetylcysteine reduces cardiovascular event patient end-stage renal failure : randomize , control trial . Circulation . 2003 Feb 25 ; 107 ( 7 ) :992-5 . 9 . Feldman L , Efrati S , Abramsohn R , Yarovoy I , Gersch E , Eviatar E , Averbukh Z , Weissgarten J. N-Acetylcysteine prevention gentamicin-induced ototoxicity hemodialysis patient . J Am Soc Nephrol 2006 ; 17 ( Suppl ) : 22A</detailed_description>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Acetylcysteine</mesh_term>
	<mesh_term>N-monoacetylcystine</mesh_term>
	<criteria>Patients ESRD , treat chronic hemodialysis Patients exclude study : 1 . Patients acute renal failure 2 . Currently treat antioxidant ( NAC , vitamin E ets . )</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>July 2007</verification_date>
	<keyword>Hemodialysis</keyword>
	<keyword>Residual Renal Function</keyword>
</DOC>